Synteract is an innovative CRO supporting biopharma companies in all phases of clinical development to bring new medicines to market. Synteract has conducted 4,000+ studies in 60+ countries, contributing to more than 240 product approvals. We offer notable expertise in dermatology, oncology, pediatrics, neuro degenerative, and rare & orphan indications.
Oncology - Synteract has managed 160+ oncology trials in the past 5 years in complex treatments like pathway-targeted therapies, chemotherapy, immunotherapy, cell-based and gene therapies. We were one of the first CROs to work in immunotherapy over 10 years ago.
Pediatrics - We’ve conducted 310+ pediatric clinical trials globally, in 25+ indications. Our pediatric cross-functional team helps clients navigate complex research to allow medicines to serve the littlest ones.
Dermatology – A leading dermatology CRO, we support novel and in-demand dermatology drug development. We’ve conducted 270+ derm trials, in 30+ indications of dermatologic disease and skin care products.
Neuro Degenerative – We’ve managed 130+ neuro degenerative trials in the past 5 years, with extensive experience in drugs addressing Alzheimer’s, Parkinson’s, ALS, MS, migraine, schizophrenia, more.
Rare & Orphan - We’ve conducted 130+ trials in rare and orphan diseases in the past 5 years alone. We specialize in unique studies that affect a small portion of the population or are otherwise “forgotten” by other treatments.
Discover how we can support your clinical trials. Visit www.synteract.com or contact us today!